Результаты поиска

Cancer immunity and immunotherapy beyond COVID-19.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Effects of exercise on inflammation in patients receiving chemotherapy: a nationwide NCORP randomized clinical trial.

PurposeA growing body of research suggests that inflammation plays a role in many chemotherapy-related toxicities such as fatigue, anxiety, and neuropathy. Regular exercise can change levels of individual cytokines (e.g., reducing IL-6, increasing IL-10); however, it is not known whether exercise during chemotherapy affects relationships between cytokines (i.e., whether cytokine concentrations change collectively vs. independently). This study assessed how 6 weeks of exercise during chemotherapy affected relationships between changes in concentrations of several cytokines.MethodsThis is a seco

Neoplastic Disorders and Cardiovascular Comorbidities in Geriatric Patients: A Simple Association?

Cardiovascular disease (CVD) and cancer frequently coexist in older patients, posing significant challenges in clinical management due to overlapping risk factors and treatment-related complications. This narrative review summarizes current knowledge on the epidemiology, shared pathophysiological mechanisms and clinical impact of neoplastic comorbidities in older adults with cardiovascular diseases. It highlights the increased mortality, morbidity and diminished quality of life resulting from the coexistence of these conditions. The review also discusses personalized management strategies, emp

Pre-Engraftment Syndrome After Autologous Stem Cell Transplantation in Relapsed or Refractory Hodgkin Lymphoma: An Association with Prior PD-1 Inhibitor Exposure.

Background and Objectives: Autologous stem cell transplantation (ASCT) remains the standard of care for relapsed or refractory Hodgkin lymphoma (R/R HL), and an increasing proportion of patients receive programmed cell death protein 1 (PD-1) inhibitors prior to transplantation. Engraftment syndrome (ES) is a noninfectious inflammatory complication classically associated with neutrophil recovery; however, early peri-transplant inflammatory manifestations remain poorly characterized and may mimic infectious complications. We aimed to evaluate peri-transplant inflammatory events after ASCT, with

Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies.

Cytokine-induced killer (CIK) cells are a heterogeneous population of immune effector cells that feature a mixed T- and Natural killer (NK) cell-like phenotype in their terminally-differentiated CD3+CD56+ subset. The easy availability, high proliferation rate and widely major histocompatibility complex (MHC)-unrestricted antitumor activity of CIK cells contribute to their particularly advantageous profile, making them an attractive approach for adoptive immunotherapy. CIK cells have shown considerable cytotoxicity against both solid tumors and hematological malignancies in vitro and in animal

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Precision medicine: The use of tailored therapy in primary immunodeficiencies.

Primary immunodeficiencies (PID) are rare, complex diseases that can be characterised by a spectrum of phenotypes, from increased susceptibility to infections to autoimmunity, allergy, auto-inflammatory diseases and predisposition to malignancy. With the introduction of genetic testing in these patients and wider use of next-Generation sequencing techniques, a higher number of pathogenic genetic variants and conditions have been identified, allowing the development of new, targeted treatments in PID. The concept of precision medicine, that aims to tailor the medical interventions to each patie

Лечебно-стойкий провокационный демиелинирующий псевдоопухоль с марбургскими особенностями: подход, основанный на описательном обзоре лечения.

Воспламенительное демиелинирование псевдотумора (ИДП) имитирует внутричерепные новообразования как с точки зрения клинического представления, так и с точки зрения изображений. МВУ с марбургскими особенностями представляют собой серьезную форму подстрекательского демиелинационного энцефаломиэлита, отмеченного драматическим наступлением, агрессивным курсом, отсутствием ремиссии и наличием повреждений центральной нервной системы, подобных опухоли. Ключевые характеристики ВПЛ в магнитно-резонансной съемке мозга включают в себя открытое или неполное расширение кольца, низкое значение обода Т2, огра

Совпадение в полном тексте источника
… Wheelchair-bound 1 g/day IVMP for 5 days Not much improvement High dose (0.4 g/kg/day) IVIg Worsening of symptoms PE associated with IV CP (300 mg every other day) Clinically: Improved Follow-up MRI: Worsening Mitoxantrone was started Discontinued, because cardiac ejection fraction fell below 50% Subcutaneous interferon-beta …

Курсы лечения заболеваний для пациентов перешли из Натализумаба в Алемтузумб: итальянский мультицентр, перспективное, наблюдательное исследование.

ВВЕДЕНИЕ: Натализумб является высокоэффективной терапией (HET) для пациентов с повторным переносом множественных склерозов (RRMS). Его продолжительное использование ограничивается риском прогрессивной многофукальной лейкоэнцефалопатии (ПМЛ) у пациентов, имеющих положительный результат в случае антиJCV антител. Цель этой работы состояла в том, чтобы оценить клиническую и радиологическую эффективность через 6 и 12 месяцев после вливания алемтузумаба в пациентов, переходящих из системы < < Натальизумаб > > , и безопасность этой стратегии ухода. Эти реальные, перспективные, многоцентри

Характеристики лиц с множественным склерозом, охватываемых государственной страховкой от наркотиков в Квебекской родильной компании.

ЦЕЛЬ: Люди, живущие с множественным склерозом, используют лекарства по нескольким признакам, однако мало что известно о том, что они употребляют по рецепту в Квебеке, в частности потому, что государственная система страхования от наркомании охватывает лишь часть населения. Мы сравнили характеристики тех, кто имеет государственную страховку от наркотиков, с теми, кто имеет частную страховку. МЕТОДЫ: В группе лиц, родившихся в 1970-1974 годах, мы идентифицировали лиц, страдающих множественным склерозом, путем применения проверенного алгоритма к административным данным о состоянии здоровья. К чис

Совпадение в полном тексте источника
… Nonetheless, many therapies like interferon-beta and glatiramer acetate remain widely used and reimbursed ( Ministère de la Santé et des Services sociaux du Québec, 2025 ). Reimbursement practices in Canada change slowly and vary by province ( Knox et al., 2020 ; Rawson and Adams, 2017 ). …

Acute Respiratory Failure After Hematopoietic Stem Cell Transplantation

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Colorectal Cancer Immunotherapy: Options and Strategies.

Colorectal cancer is the third most common cancer in the world with increasing incidence and mortality rates globally. Standard treatments for colorectal cancer have always been surgery, chemotherapy and radiotherapy which may be used in combination to treat patients. However, these treatments have many side effects due to their non-specificity and cytotoxicity toward any cells including normal cells that are growing and dividing. Furthermore, many patients succumb to relapse even after a series of treatments. Thus, it is crucial to have more alternative and effective treatments to treat CRC p

Integrated transcriptomics of multiple sclerosis peripheral blood mononuclear cells explored potential biomarkers for the disease.

BACKGROUND: Despite their importance, blood RNAs have not been comprehensively studied as potential diagnostic markers for multiple sclerosis (MS). Herein, by the integration of GSE21942 and GSE203241 microarray profiles of peripheral blood mononuclear cells, this study explored potential biomarkers for the disease. METHODS: After identification of differentially expressed genes (DEGs), functional enrichment analyses were performed, and PPI and miRNA-mRNA regulatory networks were constructed. After implementing weighted gene co-expression network analysis (WGCNA) and discovering MS-specific m

Совпадение в полном тексте источника
… Of the twelve female patients in the study, four patients had received immunomodulatory treatment, such as cortisone or interferon-beta (β-interferon), when samples were collected [ 21 ]. Table 2 Demographic data of the retrieved datasets. …

Predicting biomarkers in laryngeal squamous cell carcinoma based on the cytokine-cytokine receptor interaction pathway.

ObjectiveTo analyze and validate differential genes in the cytokine-cytokine receptor interaction CCRI pathway in laryngeal squamous cell carcinoma (LSCC) using bioinformatics and Mendelian randomization (MR) to find potential biomarkers for LSCC.MethodsFive sets of LSCC-related gene chips were downloaded from the GEO database, and four sets of combined datasets were randomly selected as the test set and one set as the validation set to screen for differential genes in the CCRI pathway; two-way Mendelian randomization was performed to analyze the causal relationship between cytokine receptor a

Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.

BackgroundC.E.R.A. (Continuous Erythropoietin Receptor Activator) is an innovative agent with unique erythropoietin receptor activity and prolonged half-life. This study evaluated C.E.R.A. once weekly (QW) or once every 3 weeks (Q3W) in patients with anemia and advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.MethodsIn this Phase II, randomized, open-label, multicenter, dose-finding study, patients (n = 218) with Stage IIIB or IV NSCLC and hemoglobin (Hb) or= 2 g/dL or achievement of Hb >or= 12 g/dL with no blood transfusion in the previous 28 days determined in two consecuti

Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma.

Hepatocellular carcinoma (HCC) is a common and aggressive cancer with a high mortality rate. The incidence of HCC is increasing worldwide, and the lack of effective screening programs often results in delayed diagnosis, making it a challenging disease to manage. Immunotherapy has emerged as a promising treatment option for different kinds of cancers, with the potential to stimulate the immune system to target cancer cells. However, the current immunotherapeutic approaches for HCC have shown limited efficacy. Since HCC arises within a complex tumour microenvironment (TME) characterized by the p

Systemic adverse effects and toxicities associated with immunotherapy: A review.

Immunotherapy is rapidly evolving secondary to the advent of newer immunotherapeutic agents and increasing approval of the current agents by the United States Food and Drug Administration to treat a wide spectrum of cancers. Immunotherapeutic agents have gained immense popularity due to their tumor-specific action. Immunotherapy is slowly transforming into a separate therapeutic entity, and the fifth pillar of management for cancers alongside surgery, radiotherapy, chemotherapy, and targeted therapy. However, like any therapeutic entity it has its own adverse effects. With the increasing use o

Natural killer T cells subsets in cancer, functional defects in prostate cancer and implications for immunotherapy.

Natural killer T cells are T lymphocytes with unique activation and effector properties. The majority of NKT cells, termed type-I or iNKT cells, recognize lipid antigens presented on MHC-like CD1d molecules. Type-I NKT cells have the capacity to rapidly secrete various cytokines upon activation, thereby regulate immune responses exerts dominant anti-tumor and anti-microbial effector functions. Specific activation of type-I NKT cells in mouse models boosts immunity and prevents metastasis, which has led to a number of phase I-II clinical trials. Since the discovery of NKT cells other subsets wi

Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline.

Despite the uncertainty of the pathogenesis of systemic lupus erythematosus, novel small molecules targeting specific intracellular mechanisms of immune cells are being developed to reverse the pathophysiological processes. These targeted molecules have the advantages of convenient administration, lower production costs, and the lack of immunogenicity. The Janus kinases, Bruton's tyrosine kinases, and spleen tyrosine kinases are important enzymes for activating downstream signals from various receptors on immune cells that include cytokines, growth factor, hormones, Fc, CD40, and B-cell recept

МикроРН в связи с иммунными заболеваниями: механизм, функции и терапевтические аспекты.

МикроРНК (миРНК) представляют собой эволюционно сохранившиеся, некодирующие молекулы РНК приблизительно 18-25 нуклеотидов по длине, которые регулируют генное выражение на посттранарном уровне. Их главным механизмом действий является пост-ранарное заглушение генов с помощью интерференции РНК, которое достигается путем привязки к дополнительным последовательности в рамках целевых посыльных РНК (mRNA). Накопляемые данные свидетельствуют о ключевой роли miRNA в развитии, дифференциации и функционировании иммунных клеток, а также в сохранении иммунной гомеостазии. Более полное понимание сложных мол